Rocket Pharmaceuticals Shares Are Trading Higher After the Company Announced That All Patients Have Bene Enrolled in the Global Phase 2 Clinical Trial Evaluating RP-A501 to Treat Male Patients With Danon Disease.
Rocket Pharmaceuticals Shares Are Trading Higher After the Company Announced That All Patients Have Bene Enrolled in the Global Phase 2 Clinical Trial Evaluating RP-A501 to Treat Male Patients With Danon Disease.
Rocket Pharmaceuticals股价上涨，因公司宣布所有患者已被纳入全球第2期临床试验，该试验评估RP-A501用于治疗Danon病的男性患者。
Rocket Pharmaceuticals Shares Are Trading Higher After the Company Announced That All Patients Have Bene Enrolled in the Global Phase 2 Clinical Trial Evaluating RP-A501 to Treat Male Patients With Danon Disease.
Rocket Pharmaceuticals股价上涨，因公司宣布所有患者已被纳入全球第2期临床试验，该试验评估RP-A501用于治疗Danon病的男性患者。
资讯热榜
更新时间